naltrexone has been researched along with clozapine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aru, GN; Bortolato, M; Fà, M; Frau, R; Gessa, GL; Manunta, M; Mereu, G; Orrù, M; Puddu, M | 1 |
| Green, AI | 1 |
| Brunette, MF; Green, AI; Noordsy, DL; O'Keefe, C | 1 |
| Bruchas, MR; Carlezon, WA; Hourguettes, NJ; Nygard, SK; Sobczak, GG | 1 |
| Cao, JL; Chen, R; Ding, L; Fei, YH; Guo, F; Jiang, Y; Liu, N; Liu, Y; Lu, C; Qi, J; Sui, Z; Wang, MM; Wang, W; Wang, X; Wang, Y; Wei, X; Wu, M; Xing, Y; Zhang, P; Zhang, Y | 1 |
4 review(s) available for naltrexone and clozapine
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
Topics: Alcohol Deterrents; Alcoholism; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders; Treatment Outcome | 2006 |
Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotics; Schizophrenia; Substance-Related Disorders; Taurine | 2008 |
15 other study(ies) available for naltrexone and clozapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Acoustic Stimulation; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Clozapine; Dizocilpine Maleate; Dopamine Agonists; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Excitatory Amino Acid Antagonists; Haloperidol; Inhibition, Psychological; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, kappa; Reflex, Startle | 2005 |
Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Basolateral Nuclear Complex; Clozapine; Conditioning, Operant; Drug-Seeking Behavior; Dynorphins; Extinction, Psychological; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Proto-Oncogene Proteins c-fos; Receptors, Opioid, kappa; Reinforcement, Psychology; Yohimbine | 2016 |
Stimulating TRPM7 suppresses cancer cell proliferation and metastasis by inhibiting autophagy.
Topics: Apoptosis; Autophagosomes; Autophagy; Cell Proliferation; Clozapine; Humans; Lysosomes; Naltrexone; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Protein Serine-Threonine Kinases; R-SNARE Proteins; Signal Transduction; TRPM Cation Channels; Zinc | 2022 |